688639 华恒生物
已收盘 11-14 15:00:00
资讯
新帖
简况
华恒生物大跌5.02% 2家券商给予增持建议
智选洞察 · 11-13 11:27
华恒生物大跌5.02% 2家券商给予增持建议
华恒生物:目前财务中心管理工作运行稳定
每日经济新闻 · 11-12 15:53
华恒生物:目前财务中心管理工作运行稳定
华恒生物:公司厌氧发酵法规模化生产L-丙氨酸的技术突破,使得 L-丙氨酸产品成本降低约50%
每日经济新闻 · 11-12 15:35
华恒生物:公司厌氧发酵法规模化生产L-丙氨酸的技术突破,使得 L-丙氨酸产品成本降低约50%
华恒生物副总经理唐思青辞职
新京报 · 11-11
华恒生物副总经理唐思青辞职
华恒生物大幅上涨 获主力净流入854万元
智选洞察 · 11-11
华恒生物大幅上涨 获主力净流入854万元
【山证新材料】华恒生物2024年三季报点评——缬氨酸价格有望企稳,关注新产品放量情况
山西证券研究所 · 11-11
【山证新材料】华恒生物2024年三季报点评——缬氨酸价格有望企稳,关注新产品放量情况
华恒生物向子公司增资6.84亿推进生物基产品项目
财中社 · 11-10
华恒生物向子公司增资6.84亿推进生物基产品项目
华恒生物最新公告:使用募集资金向全资子公司增资以实施募投项目
证券之星 · 11-10
华恒生物最新公告:使用募集资金向全资子公司增资以实施募投项目
华恒生物:关于副总经理辞职的公告
新浪财经-鹰眼工作室 · 11-10
华恒生物:关于副总经理辞职的公告
华恒生物公布定向增发融资,融资额6.84亿人民币,投资方为国元金控、创合鑫材基金等
证券之星 · 11-09
华恒生物公布定向增发融资,融资额6.84亿人民币,投资方为国元金控、创合鑫材基金等
天风证券:给予华恒生物买入评级
证券之星 · 11-07
天风证券:给予华恒生物买入评级
山西证券:给予华恒生物买入评级
证券之星 · 11-06
山西证券:给予华恒生物买入评级
圣达生物大幅上涨 华恒生物维生素B5系列产品生物制造技术入选优秀案例
智选洞察 · 11-06
圣达生物大幅上涨 华恒生物维生素B5系列产品生物制造技术入选优秀案例
卫信康创10个月新高 华恒生物维生素B5系列产品生物制造技术入选优秀案例
智选洞察 · 11-06
卫信康创10个月新高 华恒生物维生素B5系列产品生物制造技术入选优秀案例
维生素B5实现绿色生物制造
科技日报 · 11-06
维生素B5实现绿色生物制造
华恒生物大幅上涨 获融资净买入609万元
智选洞察 · 11-05
华恒生物大幅上涨 获融资净买入609万元
华恒生物:3Q24公司盈利有待改善 产品多元布局打开增长空间
长城证券 · 11-05
华恒生物:3Q24公司盈利有待改善 产品多元布局打开增长空间
华恒生物:Q3业绩持续承压 等待新产品放量保障成长
申万宏源研究 · 11-04
华恒生物:Q3业绩持续承压 等待新产品放量保障成长
兴业证券保荐与主承销的华恒生物定增发行完成
市场投研资讯 · 10-30
兴业证券保荐与主承销的华恒生物定增发行完成
华恒生物10月30日遭主力抛售2683万元 环比增加292.25%
市场透视 · 10-30
华恒生物10月30日遭主力抛售2683万元 环比增加292.25%
加载更多
公司概况
公司名称:
安徽华恒生物科技股份有限公司
所属行业:
化学原料和化学制品制造业
上市日期:
2021-04-22
主营业务:
安徽华恒生物科技股份有限公司是从事氨基酸产品的技术研发、生产、销售为一体的高新技术企业。公司主要产品为L-丙氨酸、DL-丙氨酸、β-丙氨酸、L-缬氨酸、D-泛酸钙、D-泛醇、肌醇、1,3-丙二醇、丁二酸、苹果酸、熊果苷。公司先后成功承担了科技部“863”计划、国家发改委微生物制造高技术产业化专项、科技部国家重点研发计划等科技攻关项目。公司的核心技术和产品还获得了多项国家及省部级奖项,例如“中国轻工业联合会技术发明一等奖”、“工信部制造业单项冠军产品”。
发行价格:
23.16
{"stockData":{"symbol":"688639","market":"SH","secType":"STK","nameCN":"华恒生物","latestPrice":35.42,"timestamp":1731567600000,"preClose":37.35,"halted":0,"volume":4735643,"delay":0,"floatShares":227999999,"shares":250000000,"eps":1.1974,"marketStatus":"已收盘","marketStatusCode":5,"change":-1.93,"latestTime":"11-14 15:00:00","open":37.34,"high":37.35,"low":35.18,"amount":172000000,"amplitude":0.0581,"askPrice":35.43,"askSize":21,"bidPrice":35.42,"bidSize":22,"shortable":0,"etf":0,"ttmEps":1.1974,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1731634200000},"adr":0,"adjPreClose":37.35,"symbolType":"stock_kcb","openAndCloseTimeList":[[1731547800000,1731555000000],[1731560400000,1731567600000]],"highLimit":41.09,"lowLimit":33.62,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":249723997,"pbRate":4.76,"roa":"--","roe":"9.14%","epsLYR":2.84,"committee":0.20197,"marketValue":8845000000,"floatMarketCap":8088000000,"peRate":29.580759,"changeRate":-0.0517,"turnoverRate":0.0207,"status":1,"afterMarket":{"amount":0,"volume":0,"close":35.42,"buyVolume":0,"sellVolume":0,"time":1731569639464,"indexStatus":"已收盘 11-14 15:30:00","preClose":37.35}},"requestUrl":"/m/hq/s/688639","defaultTab":"news","newsList":[{"id":"2483892014","title":"华恒生物大跌5.02% 2家券商给予增持建议","url":"https://stock-news.laohu8.com/highlight/detail?id=2483892014","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483892014?lang=zh_cn&edition=full","pubTime":"2024-11-13 11:27","pubTimestamp":1731468424,"startTime":"0","endTime":"0","summary":"11月13日,华恒生物股价大幅下跌,截至11点27分,华恒生物下跌5.02%,报36.91元/股,成交1.55亿元,换手率1.79%。此外,数据统计显示,近半年内2家券商给予增持建议,15家券商给予买入建议。资金动向截止发稿,华恒生物获得主力净流出1124万元,其中超大单流出886万元,大单流出237万元。最新财报显示,今年三季报,华恒生物实现营业收入15.39亿元,同比增长12.82%,净利润为1.70亿元,同比减少46.90%,基本每股收益为0.74元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241113112710abbbd085&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241113112710abbbd085&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0229","688639"],"gpt_icon":0},{"id":"2482721212","title":"华恒生物:目前财务中心管理工作运行稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=2482721212","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482721212?lang=zh_cn&edition=full","pubTime":"2024-11-12 15:53","pubTimestamp":1731398014,"startTime":"0","endTime":"0","summary":"每经AI快讯,有投资者在投资者互动平台提问:请问贵公司是否建立财务共享中心,如建立,请问具体是在哪一年?如果没有建立,请问贵公司是否有使用大数据等信息技术进行财务集中核算处理?华恒生物(688639.SH)11月12日在投资者互动平台表示,公司自上市以来建立起了功能比较健全的信息共享制度,目前财务中心管理工作运行稳定,公司将根据业务发展现状与需要,持续提升公司的财务管理水平与业务能力,持续加强信息共享服务建设。(记者 王可然)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241112155836a22f9379&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241112155836a22f9379&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0229","688639"],"gpt_icon":0},{"id":"2482726024","title":"华恒生物:公司厌氧发酵法规模化生产L-丙氨酸的技术突破,使得 L-丙氨酸产品成本降低约50%","url":"https://stock-news.laohu8.com/highlight/detail?id=2482726024","media":"每日经济新闻","labels":["Business Data"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482726024?lang=zh_cn&edition=full","pubTime":"2024-11-12 15:35","pubTimestamp":1731396923,"startTime":"0","endTime":"0","summary":"华恒生物11月12日在投资者互动平台表示,公司厌氧发酵法规模化生产L-丙氨酸的技术突破,使得 L-丙氨酸产品成本降低约50%,同时生产过程更为绿色环保,满足下游客户对原材料的绿色生态标签要求,促进了其在新型绿色螯合剂MGDA领域的规模化应用。公司采用自产的L-丙氨酸制备DL-丙氨酸,采用自产的 β-丙氨酸制备 D-泛酸钙,形成了自有业务的上下游产业链优势,生产成本更加低廉,亦获得了显著的成本优势,具有良好的协同发展效应。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241112153617a22f7a20&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241112153617a22f7a20&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Business Data","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0229","688639"],"gpt_icon":0},{"id":"2482258273","title":"华恒生物副总经理唐思青辞职","url":"https://stock-news.laohu8.com/highlight/detail?id=2482258273","media":"新京报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482258273?lang=zh_cn&edition=full","pubTime":"2024-11-11 15:21","pubTimestamp":1731309660,"startTime":"0","endTime":"0","summary":"11月11日,华恒生物发布公告,近日收到公司副总经理唐思青提交的书面辞职报告,唐思青因身体原因,申请辞去公司副总经理职务。辞职后,唐思青仍为公司核心技术人员并在公司担任技术专家。华恒生物称,唐思青辞职不会影响公司相关工作的正常开展。截至目前,唐思青直接持有公司股份689603股。公开资料显示,华恒生物是一家以合成生物技术为核心,通过生物制造方式,主要从事生物基产品的研发、生产、销售的国家高新技术企业。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241111152331a22bb119&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241111152331a22bb119&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0229","688639"],"gpt_icon":0},{"id":"2482495942","title":"华恒生物大幅上涨 获主力净流入854万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2482495942","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482495942?lang=zh_cn&edition=full","pubTime":"2024-11-11 10:51","pubTimestamp":1731293492,"startTime":"0","endTime":"0","summary":"11月11日,华恒生物股价大幅上涨,截至10点51分,华恒生物上涨5.00%,报37.80元/股,成交1.37亿元,换手率1.62%,振幅5.53%。资金动向截止发稿,华恒生物获得主力净流入854万元,其中超大单流入342万元,大单流入511万元。主营业务及业绩华恒生物公司主营业务为氨基酸及其衍生物产品研发、生产、销售。最新财报显示,今年三季报,华恒生物实现营业收入15.39亿元,同比增长12.82%,净利润为1.70亿元,同比减少46.90%,基本每股收益为0.74元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241111105143abb471ac&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241111105143abb471ac&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0229","688639"],"gpt_icon":0},{"id":"2482621909","title":"【山证新材料】华恒生物2024年三季报点评——缬氨酸价格有望企稳,关注新产品放量情况","url":"https://stock-news.laohu8.com/highlight/detail?id=2482621909","media":"山西证券研究所","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482621909?lang=zh_cn&edition=full","pubTime":"2024-11-11 07:59","pubTimestamp":1731283176,"startTime":"0","endTime":"0","summary":"缬氨酸、肌醇等产品价格下滑影响业绩。我们认为当前缬氨酸价格有望企稳,后续进一步下行空间有限。根据秣宝网预测,2024年缬氨酸全年生产量约为18-19万吨。由于豆粕、玉米价格的下行压力,2024年以来缬氨酸持续价格承压,此前投产缬氨酸的部分企业选择转产或减产,例如希杰减少缬氨酸产量并改造为柔性产线。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241111081436a22a9196&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241111081436a22a9196&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["159703","BK0229","688639"],"gpt_icon":0},{"id":"2482572652","title":"华恒生物向子公司增资6.84亿推进生物基产品项目","url":"https://stock-news.laohu8.com/highlight/detail?id=2482572652","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482572652?lang=zh_cn&edition=full","pubTime":"2024-11-10 19:26","pubTimestamp":1731237960,"startTime":"0","endTime":"0","summary":"财中社11月10日电华恒生物 发布关于使用募集资金向全资子公司增资以实施募投项目的公告。公司决定向全资子公司赤峰华恒合成生物科技有限公司增资4亿元,向秦皇岛华恒生物工程有限公司增资2.84亿元,以推进“年产5万吨生物基丁二酸及生物基产品原料生产基地建设项目”和“年产5万吨生物基苹果酸生产建设项目”的实施。2024年前三季度,华恒生物实现收入15.39亿元,归母净利润1.70亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241110193541abb2ef56&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241110193541abb2ef56&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0229","688639"],"gpt_icon":0},{"id":"2482604259","title":"华恒生物最新公告:使用募集资金向全资子公司增资以实施募投项目","url":"https://stock-news.laohu8.com/highlight/detail?id=2482604259","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482604259?lang=zh_cn&edition=full","pubTime":"2024-11-10 18:00","pubTimestamp":1731232858,"startTime":"0","endTime":"0","summary":"华恒生物公告,公司于2024年11月8日召开第四届董事会第十七次会议、第四届监事会第十四次会议,审议通过了《关于使用募集资金向全资子公司增资实施募投项目的议案》,同意公司使用募集资金向全资子公司赤峰华恒及秦皇岛华恒分别增资4亿元及2.84亿元以实施募投项目。以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024111000001376.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0229","688639"],"gpt_icon":0},{"id":"2482683258","title":"华恒生物:关于副总经理辞职的公告","url":"https://stock-news.laohu8.com/highlight/detail?id=2482683258","media":"新浪财经-鹰眼工作室","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482683258?lang=zh_cn&edition=full","pubTime":"2024-11-10 16:00","pubTimestamp":1731225600,"startTime":"0","endTime":"0","summary":"安徽华恒生物科技股份有限公司关于副总经理辞职的公告安徽华恒生物科技股份有限公司于近日收到公司副总经理唐思青先生提交的书面辞职报告,唐思青先生因身体原因,申请辞去公司副总经理职务。唐思青先生在担任公司副总经理期间,恪尽职守、勤勉尽责,公司董事会对唐思青先生自任职以来对公司做出的贡献致以诚挚的感谢!","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/ggzz/2024-11-10/doc-incvqmnk1617773.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/ggzz/2024-11-10/doc-incvqmnk1617773.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0229","688639"],"gpt_icon":0},{"id":"2482784441","title":"华恒生物公布定向增发融资,融资额6.84亿人民币,投资方为国元金控、创合鑫材基金等","url":"https://stock-news.laohu8.com/highlight/detail?id=2482784441","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482784441?lang=zh_cn&edition=full","pubTime":"2024-11-09 19:29","pubTimestamp":1731151751,"startTime":"0","endTime":"0","summary":"证券之星消息,根据天眼查APP于10月30日公布的信息整理,安徽华恒生物科技股份有限公司公布定向增发融资,融资额6.84亿人民币,参与投资的机构包括国元金控,创合鑫材基金,鄂旅投资本,基石资本,西藏朗润,粤开资本,君和资本。安徽华恒生物科技股份有限公司是从事氨基酸产品的技术研发、生产、销售为一体的高新技术企业。公司主要产品为丙氨酸系列产品,包括L-丙氨酸、DL-丙氨酸和β-丙氨酸等。数据来源:天眼查APP以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024110900007474.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688639","BK0229"],"gpt_icon":0},{"id":"2481087920","title":"天风证券:给予华恒生物买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2481087920","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481087920?lang=zh_cn&edition=full","pubTime":"2024-11-07 17:35","pubTimestamp":1730972123,"startTime":"0","endTime":"0","summary":"天风证券股份有限公司唐婕,张峰近期对华恒生物进行研究并发布了研究报告《氨基酸跌价拖累业绩,期待新项目投产》,本报告对华恒生物给出买入评级,当前股价为36.61元。 华恒生物 事件:华恒生物发布2024年三季报,实现营业收入15.39亿元,同比增长12.82%;归属于上市公司股东的净利润1.70亿元,同比下滑46.90%。最新盈利预测明细如下:该股最近90天内共有11家机构给出评级,买入评级9家,增持评级2家;过去90天内机构目标均价为40.82。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024110700028821.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688639","601162"],"gpt_icon":0},{"id":"2481398299","title":"山西证券:给予华恒生物买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2481398299","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481398299?lang=zh_cn&edition=full","pubTime":"2024-11-06 23:45","pubTimestamp":1730907918,"startTime":"0","endTime":"0","summary":"山西证券股份有限公司冀泳洁,王锐近期对华恒生物进行研究并发布了研究报告《缬氨酸价格有望企稳,关注新产品放量情况》,本报告对华恒生物给出买入评级,当前股价为35.6元。事件点评 缬氨酸、肌醇等产品价格下滑影响业绩。最新盈利预测明细如下:该股最近90天内共有11家机构给出评级,买入评级9家,增持评级2家;过去90天内机构目标均价为40.82。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024110600038250.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002500","688639"],"gpt_icon":0},{"id":"2481291697","title":"圣达生物大幅上涨 华恒生物维生素B5系列产品生物制造技术入选优秀案例","url":"https://stock-news.laohu8.com/highlight/detail?id=2481291697","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481291697?lang=zh_cn&edition=full","pubTime":"2024-11-06 10:50","pubTimestamp":1730861440,"startTime":"0","endTime":"0","summary":"11月06日,圣达生物股价大幅上涨,截至10点50分,圣达生物上涨5.14%,报14.32元/股,成交8763万元,换手率3.69%,振幅5.65%。消息解读在2024中国生物制造大会上,首次发布了“2024生物制造产业化十大优秀案例”。安徽华恒生物科技股份有限公司的“维生素B5系列产品的生物制造”成功入选。华恒生物研发的维生素B5系列产品生物制造技术,实现了以可再生生物质碳源发酵生产D-泛解酸,从而推动了维生素B5系列产品的生物制造进程。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241106105108a21a5370&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241106105108a21a5370&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688639","BK0191","BK0229","603079","BK0226"],"gpt_icon":0},{"id":"2481699988","title":"卫信康创10个月新高 华恒生物维生素B5系列产品生物制造技术入选优秀案例","url":"https://stock-news.laohu8.com/highlight/detail?id=2481699988","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481699988?lang=zh_cn&edition=full","pubTime":"2024-11-06 09:59","pubTimestamp":1730858372,"startTime":"0","endTime":"0","summary":"11月06日,卫信康股价大幅上涨,截至09点59分,卫信康上涨5.41%,报10.71元/股,创近10个月新高,成交4337万元,换手率0.96%,振幅5.91%。消息解读在2024中国生物制造大会上,首次发布了“2024生物制造产业化十大优秀案例”。安徽华恒生物科技股份有限公司的“维生素B5系列产品的生物制造”成功入选。华恒生物研发的维生素B5系列产品生物制造技术,实现了以可再生生物质碳源发酵生产D-泛解酸,从而推动了维生素B5系列产品的生物制造进程。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241106100054aba39533&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241106100054aba39533&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0191","BK0229","603676","688639","BK0239"],"gpt_icon":0},{"id":"2481663442","title":"维生素B5实现绿色生物制造","url":"https://stock-news.laohu8.com/highlight/detail?id=2481663442","media":"科技日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481663442?lang=zh_cn&edition=full","pubTime":"2024-11-06 02:44","pubTimestamp":1730832243,"startTime":"0","endTime":"0","summary":"随着人们对环保的重视,人们将目光转向维生素B5系列产品的生物制造。养殖动物缺乏维生素B5会出现多种生长和健康问题,包括生长速度放缓、体重减轻、皮肤及黏膜损伤、神经系统紊乱、胃肠失调、肾上腺功能缺陷、行走困难等。鉴于此,维生素B5作为重要的饲料添加剂,已被广泛应用于家禽、猪、鱼类等动物的饲料中。郭恒华表示,未来,华恒生物将以生产成本和生态效益的双重优势,实现低碳、环保、高效的维生素B5系列产品生物制造。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241106024406aba2ab06&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241106024406aba2ab06&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688639","BK0229"],"gpt_icon":0},{"id":"2481512478","title":"华恒生物大幅上涨 获融资净买入609万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2481512478","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481512478?lang=zh_cn&edition=full","pubTime":"2024-11-05 13:01","pubTimestamp":1730782868,"startTime":"0","endTime":"0","summary":"资金动向截止发稿,华恒生物获得主力净流出176万元,其中超大单流出596万元,大单流入420万元。融资融券方面,华恒生物11月04日获得融资净买入609万元,当日该股融资余额为2.94亿元,当较前一日增加2.12%;该股融券余额为120万元,融券余量为3.38万股,比上日增加2.42%。最新财报显示,今年三季报,华恒生物实现营业收入15.39亿元,同比增长12.82%,净利润为1.70亿元,同比减少46.90%,基本每股收益为0.74元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241105130517aba08678&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241105130517aba08678&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0229","688639"],"gpt_icon":0},{"id":"2481578478","title":"华恒生物:3Q24公司盈利有待改善 产品多元布局打开增长空间","url":"https://stock-news.laohu8.com/highlight/detail?id=2481578478","media":"长城证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481578478?lang=zh_cn&edition=full","pubTime":"2024-11-05 00:00","pubTimestamp":1730736000,"startTime":"0","endTime":"0","summary":"事件:2024 年10 月28 日,华恒生物发布2024 年三季报,公司2024 前三季度营业收入为15.39 亿元,同比上涨12.82%;归母净利润1.70 亿元,同比下跌46.90%;扣非净利润1.66 亿元,同比下跌47.41%。对应3Q24 公司实现营业收入5.23 亿元,同比上涨1.66%,环比上涨1.43%;归母净利润0.20 亿元,同比下跌84.32%,环比下跌68.04%。公司3Q24 归母净利润下跌主要原因是缬氨酸产品价格较去年同期下跌,同时,公司经营规模持续扩大,相关费用较去年同期增加。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024110518112795bdd095&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024110518112795bdd095&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688639","BK0229"],"gpt_icon":0},{"id":"2480076583","title":"华恒生物:Q3业绩持续承压 等待新产品放量保障成长","url":"https://stock-news.laohu8.com/highlight/detail?id=2480076583","media":"申万宏源研究","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480076583?lang=zh_cn&edition=full","pubTime":"2024-11-04 00:00","pubTimestamp":1730649600,"startTime":"0","endTime":"0","summary":"24Q3 公司业绩低于预期,我们认为主要原因:1)缬氨酸价格持续下行,且竞争从国内渗透到海外市场,导致前期盈利情况较好的出口业务受到影响;2)新项目投产后爬坡、放量低于预期。24Q3 竞品豆粕价格下行导致氨基酸景气偏弱,缬氨酸竞争加剧价格持续下行,丙氨酸、肌醇等产品贡献相对稳定利润。核心产品价格下滑导致利润率水平出现明显下滑。截至2024 年三季报,公司固定资产12.61 亿元,在建工程18.32 亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202411042051229f591d1a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202411042051229f591d1a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688639","BK0229"],"gpt_icon":0},{"id":"2479058788","title":"兴业证券保荐与主承销的华恒生物定增发行完成","url":"https://stock-news.laohu8.com/highlight/detail?id=2479058788","media":"市场投研资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479058788?lang=zh_cn&edition=full","pubTime":"2024-10-30 21:08","pubTimestamp":1730293680,"startTime":"0","endTime":"0","summary":"2024年10月30日,华恒生物公告以33.14元/股的价格向特定对象发行2112万股A股普通股股票,完成了总额约7.00亿元的定增,兴业证券担任本次发行的保荐机构和联席主承销商。这是兴业证券累计完成的第327个股权融资项目。兴业证券保荐承销能力备受认可兴业证券以服务实体经济高质量发展为初心,为客户提供全面的保荐承销服务。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2024-10-30/doc-incuixut6649202.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2024-10-30/doc-incuixut6649202.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0276","BK0183","BK0028","BK0229","BK0188","688639","BK0012","601377"],"gpt_icon":0},{"id":"2479822652","title":"华恒生物10月30日遭主力抛售2683万元 环比增加292.25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2479822652","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479822652?lang=zh_cn&edition=full","pubTime":"2024-10-30 15:19","pubTimestamp":1730272799,"startTime":"0","endTime":"0","summary":"10月30日, 华恒生物股价跌3.26%,报收35.02元,成交金额1.67亿元,换手率2.09%,振幅3.98%,量比0.50。华恒生物今日主力资金净流出2683万元,上一交易日主力净流出684万元,今日环比增加292.25%。该股近5个交易日下跌4.71%,主力资金累计净流入3378万元;近20日主力资金累计净流入2.54亿元,其中净流入天数为14日。净流出前三个股分别为合盛硅业、华恒生物、广东宏大。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241030154425a1f8c3ef&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241030154425a1f8c3ef&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0229","688639"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2021-04-22","address":"安徽省合肥市长丰县双凤工业区","stockEarnings":[{"period":"1week","weight":-0.0325},{"period":"1month","weight":0.0766},{"period":"3month","weight":-0.0245},{"period":"6month","weight":-0.5451},{"period":"1year","weight":-0.5214},{"period":"ytd","weight":-0.5863}],"companyName":"安徽华恒生物科技股份有限公司","boardCode":"AI0026","perCapita":"30749股","boardName":"化学原料和化学制品制造业","registeredCapital":"24972万元","compareEarnings":[{"period":"1week","weight":-0.0262},{"period":"1month","weight":0.0558},{"period":"3month","weight":0.1738},{"period":"6month","weight":0.0716},{"period":"1year","weight":0.0999},{"period":"ytd","weight":0.1361}],"survey":" 安徽华恒生物科技股份有限公司是从事氨基酸产品的技术研发、生产、销售为一体的高新技术企业。公司主要产品为L-丙氨酸、DL-丙氨酸、β-丙氨酸、L-缬氨酸、D-泛酸钙、D-泛醇、肌醇、1,3-丙二醇、丁二酸、苹果酸、熊果苷。公司先后成功承担了科技部“863”计划、国家发改委微生物制造高技术产业化专项、科技部国家重点研发计划等科技攻关项目。公司的核心技术和产品还获得了多项国家及省部级奖项,例如“中国轻工业联合会技术发明一等奖”、“工信部制造业单项冠军产品”。","serverTime":1731605142863,"listedPrice":23.16,"stockholders":"7426人(较上一季度增加36.71%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"华恒生物(688639)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供华恒生物(688639)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"华恒生物,688639,华恒生物股票,华恒生物股票老虎,华恒生物股票老虎国际,华恒生物行情,华恒生物股票行情,华恒生物股价,华恒生物股市,华恒生物股票价格,华恒生物股票交易,华恒生物股票购买,华恒生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"华恒生物(688639)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供华恒生物(688639)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}